Nuveen Asset Management LLC lifted its position in shares of Innoviva, Inc. (NASDAQ:INVA) by 0.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 511,961 shares of the biotechnology company’s stock after buying an additional 1,304 shares during the quarter. Nuveen Asset Management LLC’s holdings in Innoviva were worth $6,343,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in the company. Wells Fargo & Company MN increased its holdings in Innoviva by 0.4% during the 4th quarter. Wells Fargo & Company MN now owns 246,393 shares of the biotechnology company’s stock valued at $3,052,000 after acquiring an additional 981 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Innoviva by 2.7% in the fourth quarter. The Manufacturers Life Insurance Company now owns 39,076 shares of the biotechnology company’s stock valued at $484,000 after purchasing an additional 1,021 shares during the last quarter. Penserra Capital Management LLC increased its stake in shares of Innoviva by 174.9% during the 4th quarter. Penserra Capital Management LLC now owns 2,375 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,511 shares in the last quarter. Baird Financial Group Inc. grew its stake in Innoviva by 11.1% in the 4th quarter. Baird Financial Group Inc. now owns 16,664 shares of the biotechnology company’s stock worth $206,000 after acquiring an additional 1,660 shares during the period. Finally, Ellevest Inc. purchased a new stake in Innoviva in the 4th quarter worth approximately $25,000. 71.48% of the stock is owned by institutional investors and hedge funds.
In other Innoviva news, Director Innoviva, Inc. bought 1,867,912 shares of Innoviva stock in a transaction that occurred on Tuesday, January 26th. The shares were acquired at an average price of $3.25 per share, for a total transaction of $6,070,714.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.32% of the company’s stock.
Innoviva (NASDAQ:INVA) last announced its quarterly earnings results on Wednesday, February 3rd. The biotechnology company reported $0.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.40 by $0.08. The company had revenue of $90.48 million for the quarter. Innoviva had a net margin of 67.16% and a return on equity of 53.99%. As a group, equities research analysts anticipate that Innoviva, Inc. will post 2.4 earnings per share for the current year.
Several analysts have commented on INVA shares. TheStreet cut shares of Innoviva from a “b-” rating to a “c+” rating in a research note on Thursday, February 25th. Zacks Investment Research lowered shares of Innoviva from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 13th.
Innoviva, Inc engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA.
See Also: Understanding the two types of arbitrage
Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva, Inc. (NASDAQ:INVA).
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.